三级片无码高清免费国产,中文字幕一区二区三区乱,国内精品久久久久久99蜜桃,亚洲一区电影网站在线观看

Stock(600222)Hot line:010-61006450

News

Understand the latest news of Leadingpharm

Leadingpharm and China Biology Signed an Agreement of Phase-I Clinical Research on a New Drug for Type 2 Diabetes

Release time:2021-07-28

Recently, Leadingpharm signed a cooperation agreement with China Biology on the phase I clinical research project of "insulin secreting peptide fusion protein injection". The project is developed by Lanzhou Institute of biological products of China Biology. Leadingpharm will be responsible for providing phase I clinical research services. The conclusion of this cooperation marks that Leadingpharm has officially joined the ranks of clinical CRO suppliers of China Biology and started the journey of strategic cooperation.
 

China Biology

China Biology was found in 1919 and is directly under the leadership of the National Health Commission. Now it is an important member enterprise of China Pharmaceutical Group, which is an enterprise of the world's top 500. It is a comprehensive biopharmaceutical enterprise in China with a long history, complete products and large scale, integrating scientific research, production, sales and postgraduate training. It has 12 secondary subsidiaries including Shanghai Institute of Biological Products, Lanzhou Institute of Biological Products and Wuhan Institute of Biological Products and 76 subsidiaries below secondary level, with 12551 employees. The company has a rich product line, covering six biological products fields: human vaccine, blood products, medical beauty, animal health care, antibody drugs and medical diagnosis. The annual output of 50 kinds of vaccines for human use can exceed 700 million doses, ranking sixth in the world, providing more than 80% of the vaccines for national immunization planning. Listed companies with an annual plasma collection volume of more than 1500 tons are producing 11 kinds of blood products. As the only botulinum toxin manufacturer certified and approved by the government in China, products are highly recognized by the market, providing the society with all-round and high-quality services for animal vaccines and related animal biological products. It has a complete antibody drug industry chain and a large molecular diagnosis industry chain with distinctive characteristics.
 

Leadingpharm

Leadingpharm (stock code: 600222) was established in 2005. It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services to the whole world. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises "for many years (ranked first in 2019). The company has nearly 1,000 R&D personnel, 80% of whom have a master's degree or above, all from well-known universities at home and abroad, specializing in medicinal chemistry, drug analysis and pharmaceutical preparations. The core R&D personnel have been engaged in the professional research work for many years, have rich experience in the development and production of new drugs, and have a thorough interpretation of registration regulations and guidelines. At present, more than 500 clinical studies have been completed, 50 to 100 BE studies and 10 to 20 clinical studies of Class I new drugs can be completed every year. Based on the rich experience in pharmaceutical R & D and clinical CRO of Leadingpharm and the CXO Integrated Service System Platform, it can meet the different needs of enterprises and provide good help for the transformation of innovative drugs.Based on Leadingpharm’s rich experience in pharmaceutical R & D and Clinical CRO and its CXO integrated service system platform, it can meet the different needs of enterprises and provide good help for the transformation of innovative drugs.
 

It is reported that "Insulin Secreting Peptide Fusion Protein Injection" is a GLP-1 receptor agonist. In vivo, it can promote insulin in islet B cells in a glucose concentration dependent manner by binding with GLP-1 receptor and activating the receptor, and reduce the secretion of glucagon in cells, so as to reduce blood glucose and have the effect of safe and effective control of blood samples. Compared with insulin, sulfonylurea and other routine drugs, the insulin secreting peptide fusion protein injection is expected to achieve good blood glucose control goal once every 10~15 days, and is more conducive to the treatment of patients with type 2 diabetes.

 

With the signing of the cooperation agreement between the two sides, the project will officially enter the phase I clinical research stage. The two sides will set up a project team to tackle tough problems and speed up the quality and efficiency of the project, and strive to promote early release of the fusion protein injection of insulin secreting peptide, which will bring more convenient treatment options for diabetics. Meanwhile, the two sides will continue to explore more levels of cooperation opportunities, access China's biological innovative drug platform with the CXO Whole Industry Chain Service System of Leadingpharm, inject new momentum into the R & D and transformation of innovative drugs, and jointly promote the development of China's pharmaceutical industry.
 

-END-

轉(zhuǎn)載聲明:未經(jīng)本網(wǎng)或本網(wǎng)權(quán)利人授權(quán),不得轉(zhuǎn)載、摘編或利用其他方式使用上述作品。已經(jīng)本網(wǎng)或本網(wǎng)權(quán)利人授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來源:新領(lǐng)先醫(yī)藥科技”。

Recommend

国产精品内射后入合集| 日韩精品一区二区三区日韩| 国产精品无码一二三视频| 欧洲成本人网站毛片无码| 无码吃奶揉捏奶头高潮视频| 久久精品国产这里是免费| 婷婷国产v亚洲v欧美久久| 蜜桃臀无码内射一区二区三区| 国产成人精品日本亚洲i8| 成人AV片无码免费网站| 久久久久久午夜精品网站| 国产 无码 AV在线 | 拍国产真实伦偷精品| 亚洲av乱码专区国产精品| 国产精品久久久久久人妻精品| 久久久精品老熟女诱惑我| 人妻丰满熟妇αv无码区| 国产精品久久久久久蜜桃| 亚洲 欧美 另类 综合| 夜色激情网在线观看视频| 色老头久久久久久久久久| 亚洲香蕉中文网| 欧美18禁一区二区三区| 免费av无码久久一本通| 国产精品女人精品天天久久| 国产欧美亚洲综合第一区| 国产午夜在线精品三级a| 国产不卡一区二区三区在线| 亚洲第一a美女视频黄频道| 国产亚洲欧美精品视频网站| 中文字幕在线第一页日韩| 国产亚洲精品女人久久久| 国产成人精品亚洲日本在线观看| 日本亚洲色大成网站WW| 嗯嗯嗯!用力插在线视频| 性色av极品无码专区亚洲| 天天舔天天操天天爱天天| 在线观看精品福利片香蕉| 露脸的国产极品在线观看| 午夜爱爱免费视频无遮挡| sci一区二区怎么区分|